Splenopentin
/ Synthetic pentapeptide derived from spleninALIAS · Spleen-derived pentapeptide · SP-5 · Arg-Lys-Glu-Val-Tyr
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Russian-origin literature on a synthetic pentapeptide derived from a region of splenin (the parent splenic peptide); Western primary-literature replication is sparse. Limited published in-vitro and rodent evidence.
Reported in Russian and Eastern European literature to enhance T-cell maturation and natural killer cell activity in models of immunodeficiency. Receptor and signalling pathway have not been fully characterised; mechanistic claims rest on cell-culture lymphocyte function assays.
Tier 4. Sparse published evidence outside the original development line. No Phase 1 trial of synthetic splenopentin has been published in Western literature.
No formal human safety database in the Western literature.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin small-peptide literature on immune bioregulators — Khavinson-tradition publications — has not been replicated under modern Western RCT methodology. Vendor sales of these molecules trade on an evidence base that the broader scientific community has not independently validated.